HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- chloro- 3- (5- methyl- 3- ((4- (2- pyrrolidin- 1- ylethoxy)phenyl)amino)- 1,2,4- benzotriazin- 7- yl)phenol

a protein kinase inhibitor

Also Known As:

TG 100801; TG-100801; TG100801

Networked: 4 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenols: 677
        4-chloro-3-(5-methyl-3-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)-1,2,4-benzotriazin-7-yl)phenol: 4
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Triazines: 306
    - 4-chloro-3-(5-methyl-3-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)-1,2,4-benzotriazin-7-yl)phenol: 4

Experts

1.	Noronha, Glenn: 3 articles (01/2009 - 03/2008)
2.	Soll, Richard: 3 articles (01/2009 - 03/2008)
3.	Cao, Jianguo: 2 articles (01/2009 - 03/2008)
4.	Chow, Chun P: 2 articles (01/2009 - 03/2008)
5.	Mak, Chi Ching: 2 articles (01/2009 - 03/2008)
6.	McPherson, Andrew: 2 articles (01/2009 - 03/2008)
7.	Pathak, Ved P: 2 articles (01/2009 - 03/2008)
8.	Renick, Joel: 2 articles (01/2009 - 03/2008)
9.	Zeng, Binqi: 2 articles (01/2009 - 03/2008)
10.	Akiyama, Hideo: 2 articles (07/2008 - 03/2008)

Related Diseases

1.	Macular Degeneration (Age-Related Maculopathy) 01/01/2009 - "Two benzotriazine based compounds, tirapazamine for the treatment of cancer and TG100801 for the treatment of age-related macular degeneration, have entered clinical trials." 03/27/2008 - "Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration."
2.	Neoplasms (Cancer) 01/01/2009 - "Two benzotriazine based compounds, tirapazamine for the treatment of cancer and TG100801 for the treatment of age-related macular degeneration, have entered clinical trials."
3.	Inflammation (Inflammations) 01/01/2009 - "Some of them are already available in human trials or even approved vascular epithelial growth factor (VEGF) blockers such as Macugen, Lucentis, Avastin, VEGF Trap-Eye and Cand5; VEGF receptor blockers such as TG100801, vatalanib, pazopanib, Sirna-027 and a vaccine approach; inflammation inhibitors and immunosuppressants such as Retaane, Kenalog, ARC1905, POT-4, OT-551. "
4.	Weight Loss (Weight Reduction) 07/01/2008 - "Neither TG100801 nor TG100572 were detectable in plasma following topical delivery of TG100801, and adverse safety signals (such as weight loss) were not observed even with prolonged dosing schedules. "
5.	Retinal Vein Occlusion 07/01/2008 - "Topical TG100801 significantly suppressed laser-induced CNV in mice, and reduced fluorescein leakage from the vasculature and retinal thickening measured by optical coherence tomography in a rat model of retinal vein occlusion. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
3.	Intercellular Signaling Peptides and Proteins (Growth Factors)
4.	Vaccines
5.	Triamcinolone Acetonide (Azmacort)
6.	Prodrugs
7.	Immunosuppressive Agents (Immunosuppressants)
8.	Benzoates (Benzoate)
9.	Tirapazamine (SR 4233)
10.	Ranibizumab (Lucentis)

Related Therapies and Procedures

1.	Lasers (Laser)